On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

By Sandi Wong, Staff Writer | Oct 10, 2019 | 11:37 PM GMT

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two of the compounds.

Reata Pharmaceuticals Inc. (NASDAQ:RETA), which gained $9.89 (13%) to $85.98 Thursday, expects data by

Read the full 511 word article

How to gain access

Continue reading with a
two-week free trial.